Applied Filters
SPC waiver stockpiling provision attracts criticism
While the final text of the European Council’s agreement on a supplementary protection certificate manufacturing waiver has yet to be released, the reported stockpiling provision has attracted criticism.
CJEU backs Warner-Lambert in marketing authorisation dispute
The Court of Justice of the European Union has issued a judgment in favour of Warner-Lambert amid a dispute between the American pharmaceutical company and an administrative body in the Netherlands.
EU court rejects Bayer’s heart-related TM
Bayer suffered defeat at the hands of the EU General Court today, with the rejection of its attempt to register what the court deemed to be heart-related trademark.
EU court throws out dentistry TM application
The EU General Court has dismissed an appeal from German company Nemius Group against a decision to refuse registration for its ‘Dentaldisk’ mark.
UK could lose out on Europe-wide drug safety system post-Brexit
UK patients could be more exposed to counterfeit medicines than EU patients in the event of a ‘no deal’ Brexit, because access to an initiative aimed at protecting patients from fake drugs could be lost.
GSK and Merck KGaA unite in €3.7bn immunotherapy deal
UK headquartered GSK has made another move in the oncology space, signing a potential €3.7 billion immunotherapy deal with Germany-based Merck KGaA.
Merck signs DNA licensing deal with Vertex
German pharmaceutical company Merck Group has granted US biotech firm Vertex a licence to two DNA-dependent protein kinases inhibitors.
HGF adds IP partner in The Hague office
Law firm HGF has added Leythem Wall as a partner.
Novartis enters AI partnership with Oxford University
Novartis and the University of Oxford’s Big Data Institute have joined forces to use artificial intelligence for improving drug development, initially in the areas of multiple sclerosis, dermatology and rheumatology.
Life sciences lawyers shocked and concerned amid Brexit uncertainty
Lawyers have told LSIPR they are concerned about the continuing UK political uncertainty having a negative impact on life sciences investment and the Unified Patent Court.
